carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa]

What the CMS Formulary Data Shows for carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa]

Per the CMS 2026 Part D formulary file, carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa] (RxNorm concept RXCUI 1599852, generic name carbidopa) appears on 5 distinct formulary files spanning 50 Medicare Part D plan offerings - 1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 5, with a cross-plan average of Tier 3.8.

Real-world access to carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 20% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,842 Part D beneficiaries filled carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa] in 2023, with total plan-and-beneficiary spending of $8,630,589 and an average per-beneficiary annual cost of $1,782.44. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension [Duopa] today.